Loan Loss Reserves / Non-Performing Loans (Quarterly)

Loan Loss Reserves / Non-Performing Loans: Allowance for bad loans as a portion of total loans made. Calculated as: Loan Loss Reserves / Non-Performing Loans

West Pharmaceutical Services, Inc. (WST) Loan Loss Reserves / Non-Performing Loans data is not available.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$804.60M
Net Income	$140.00M
Cost of Goods Sold	$510.30M
Gross Profit	$294.30M
Operating Expenses	$637.00M
Operating Income	$167.60M
Non-Operating Income/Expense	$4.30M
Pre-Tax Income	$171.90M
Normalized Pre-Tax Income	$171.90M
Income after Taxes	$137.90M
Income from Continuous Operations	$140.00M
Consolidated Net Income/Loss	$140.00M
Normalized Income after Taxes	$137.90M
EBIT	$167.60M
EBITDA	$210.60M
Weighted-Average Shares Outstanding (Basic)	72.20M
Weighted-Average Shares Outstanding (Diluted)	72.60M
Earnings per Share (EPS) (Basic)	$1.94
Earnings per Share (EPS) (Diluted)	$1.92
Balance Sheet Financials
Current Assets	$1.82B
Property, Plant, and Equipment	$1.74B
Long-Term Assets	$2.28B
Total Assets	$4.11B
Current Liabilities	$635.40M
Long-Term Debt	$202.70M
Long-Term Liabilities	$418.90M
Total Liabilities	$1.05B
Common Equity	$3.05B
Tangible Shareholders Equity	$2.93B
Shareholders Equity	$3.05B
Common Shares Outstanding	71.90M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$503.70M
Cash Flow from Investing Activities	$-209.80M
Cash Flow from Financial Activities	$-173.40M
Beginning Cash	$484.60M
End Cash	$628.50M
Increase/Decrease in Cash	$143.90M
Stock-Based Compensation	$17.10M
Common Stock Dividends Paid	$-45.40M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.87
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.06
Debt to Equity Ratio	0.07
Gross Margin	36.58%
Operating Margin	20.83%
EBIT Margin	20.83%
EBITDA Margin	--
Pre-Tax Profit Margin	21.36%
Profit Margin	17.40%
Free Cash Flow	$293.90M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.20
Inventory Turnover	1.17
Receiveable Turnover	1.29
Days Sales in Receivables	69.91
Return on Equity	4.59%
Return on Tangible Equity	4.77%
Return on Assets	3.41%
Return on Investments	4.30%
Book Value Per Share	$42.44
Free Cash Flow per Share	$4.05
Operating Cash Flow per Share	$6.94

Data from Zacks Investment Research, Inc.